As an adjunct to standard of care in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), liraglutide reduced the risk for major cardiovascular (CV) events and all-cause mortality. In the LEADER trial, patients were randomized 1:1 to liraglutide or placebo, both in addition to standard of care. The primary outcome was composite of CV death, non-fatal myocardial infarction (MI), or non-fatal stroke and the secondary outcomes included all-cause mortality and individual components of the primary composite outcome. Researchers found:
- Overall, 2,158 and 7,182 patients had baseline eGFR <60 or ≥60 mL/min/1.73 m2, respectively.
- In patients with eGFR <60 mL/min/1.73 m2, risk reduction for the primary composite CV outcome with liraglutide was greater (hazard ratio [HR] 0.69) vs those with eGFR ≥60 mL/min/1.73 m2 (HR 0.94).
- There was no consistent effect modification with liraglutide across finer eGFR subgroups.
Mann JFE, Fonseca V, Mosenzon O, et al. Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes and chronic kidney disease: Results from the LEADER Trial. [Published online ahead of print October 3, 2018]. Circulation. doi:10.1161/CIRCULATIONAHA.118.036418.